on January 19, 2006
Published online before print January 19, 2006, doi: 10.1161/01.ATV.0000204635.75748.0f
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on July 22, 2005
Accepted on December 15, 2005
Eplerenone With Valsartan Effectively Reduces Atherosclerotic Lesion by Attenuation of Oxidative Stress and Inflammation
Jun Suzuki ;
From the Department of Molecular and Cellular Biology (J.S., M.I., M.M., A.O., T.Y., M.H.), Division of Medical Biochemistry and Cardiovascular Biology, and Second Department of Internal Medicine (J.S., A.O., T.Y., J.H.), Ehime University School of Medicine, Japan. J.S.’s current address: Cardiovascular Research Institute, University of Rochester, 601 Elmwood Ave, Box 679/CVRI, Rochester, NY 14642.
* To whom correspondence should be addressed. E-mail: horiuchi{at}m.ehime-u.ac.jp.
Objective--Angiotensin II contributes to atherogenesis, mainly through oxidative stress and inflammation. Recent data suggest that aldosterone is implicated in some effects of angiotensin II. We hypothesized that aldosterone could directly contribute to oxidative stress and atherosclerotic lesion formation.
Methods and Results--Male apolipoprotein E-deficient mice 6 weeks of age were placed on a normal diet or 1.25% high-cholesterol diet. After 6 weeks of the high-cholesterol diet, a marked increase in atherosclerotic lesion formation was observed in the aorta, accompanied by significant elevation of plasma cholesterol level. Production of superoxide anion and expression of NAD(P)H oxidase subunit p47phox, tumor necrosis factor-
, and monocyte chemoattractant protein-1 in the aorta were increased with the high-cholesterol diet. Eplerenone (1.67 g/kg in high-cholesterol diet) did not affect blood pressure or plasma cholesterol but decreased the atherosclerotic area by nearly 70% (P<0.05), associated with attenuation of oxidative stress and inflammatory response. Valsartan (0.5 mg/kg per day) also decreased the atherosclerotic lesion, whereas coadministration of valsartan and eplerenone further decreased it. Moreover, aldosterone (0.1 µmol/L) enhanced NADPH oxidase activity in cultured vascular smooth muscle cells.
Conclusions--These results suggest that aldosterone may play a critical role in atherogenesis subsequent to oxidative stress in part independent of angiotensin II-mediated signaling, and that eplerenone could prevent atherosclerosis by attenuating oxidative stress and inflammation.
Key words: angiotensin • aldosterone • receptors • oxidative stress • atherosclerosis
This article has been cited by other articles:
 |
|
 |
|
  A. J Rickard and M. J Young Corticosteroid receptors, macrophages and cardiovascular disease J. Mol. Endocrinol., June 1, 2009; 42(6): 449 - 459. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Nicholls, E. M. Tuzcu, D. M. Brennan, J.-C. Tardif, and S. E. Nissen Cholesteryl Ester Transfer Protein Inhibition, High-Density Lipoprotein Raising, and Progression of Coronary Atherosclerosis: Insights From ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation) Circulation, December 9, 2008; 118(24): 2506 - 2514. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.C. Montezano, G.E. Callera, A. Yogi, Y. He, R.C. Tostes, G. He, E.L. Schiffrin, and R.M. Touyz Aldosterone and Angiotensin II Synergistically Stimulate Migration in Vascular Smooth Muscle Cells Through c-Src-Regulated Redox-Sensitive RhoA Pathways Arterioscler Thromb Vasc Biol, August 1, 2008; 28(8): 1511 - 1518. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. de Haan, J. de Vries-van der Weij, J. W.A. van der Hoorn, T. Gautier, C. C. van der Hoogt, M. Westerterp, J. A. Romijn, J. W. Jukema, L. M. Havekes, H. M.G. Princen, et al. Torcetrapib Does Not Reduce Atherosclerosis Beyond Atorvastatin and Induces More Proinflammatory Lesions Than Atorvastatin Circulation, May 13, 2008; 117(19): 2515 - 2522. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. J. Brown Aldosterone and Vascular Inflammation Hypertension, February 1, 2008; 51(2): 161 - 167. [Full Text] [PDF]
|
|
|
|
|
|
S. Zadelaar, R. Kleemann, L. Verschuren, J. de Vries-Van der Weij, J. van der Hoorn, H. M. Princen, and T. Kooistra Mouse Models for Atherosclerosis and Pharmaceutical Modifiers Arterioscler Thromb Vasc Biol, August 1, 2007; 27(8): 1706 - 1721. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Cascella, S. Palomba, L. Tauchmanova, F. Manguso, S. Di Biase, D. Labella, F. Giallauria, C. Vigorito, A. Colao, G. Lombardi, et al. Serum Aldosterone Concentration and Cardiovascular Risk in Women with Polycystic Ovarian Syndrome J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4395 - 4400. [Abstract] [Full Text] [PDF]
|
|